Gilead HCV combo granted speedy EU assessment
This article was originally published in Scrip
Gilead Sciences' once-daily, fixed dose combination of ledipasvir and sofosbuvir has been granted accelerated assessment by the European Medicines Agency, following the company's Marketing Authorisation Application (MAA) in February. The speeded up process could shorten the review time by about two months. The hepatitis C treatment, if approved, could therefore be available in the EU by the end of 2014.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.